A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.
While cautioning that it's still early days, experts said the data - especially those showing much lower toxicity - raise the prospect that the therapy could replace autologous CAR-Ts, if its efficacy remains the same.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The Phase I study is planned to enroll 24 patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma and will be run under Allogene's collaboration with Servier.
The filing comes one week after the company, founded earlier this year with a $300 million Series A round by two former Kite executives, raised $120 million in a private financing.
In less than a decade, the chief patient officer - and similar roles with different titles - has become a key part of the healthcare industry executive team.
Led by two Kite founders, the company launched with $300 million in VC funding in April and plans a registration trial of Servier's UCART19 and clinical development of its own allogeneic CAR-Ts next year.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.